Is HELP a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Phase 3 depression readout, with revenue (ttm) at ~$0 (pre-revenue, under $1M). The bear case rests on as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. Analysts covering it are spread from $7.98 to $69.86, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $7.98, +0.8% from the $7.92 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Phase 3 depression readout. The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst, with topline data anticipated around Q4 2026. The most optimistic analyst target on HELP is $69.86, +782.1% from the $7.92 price. That figure is only reachable if this thesis works close to its best case.

As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile and can move sharply on single data points. The most pessimistic published target is $7.98, +0.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Phase 3 depression readout) stalling in the reported numbers rather than in the narrative, the risk above (as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

HELP is Cybin Inc., a clinical-stage biotech that now operates under the name Helus Pharma. It moved its U.S. listing to the Nasdaq under HELP in early 2026 after previously trading as CYBN on NYSE American.

It develops psychedelic-derived neuroactive compounds, including a deuterated psilocybin analog and a deuterated DMT analog, designed as supervised therapies for major depressive disorder and generalized anxiety disorder.

No meaningful revenue. Cybin is pre-revenue and reported under $1 million in sales, so it operates at a loss while funding clinical trials, which is typical for a clinical-stage biotech.